Abstract:Abstract Background: Tumors often demonstrate initial responses to cisplatin-based chemotherapy in treating non-small cell lung cancer (NSCLC), but eventually develop resistance and limit the success of therapy. We investigated whether IL-6 signaling is important in developing cisplatin-resistance of NSCLC and explore if targeting IL-6 signaling may increase tumor sensitivity to cisplatin. Methods: We performed in vitro cytotoxicity test using the IL-6 knocked down and scramble (sc) control A549 and H157 NSCLC cell lines (A549IL-6si/sc and H157IL-6si/sc). We also performed in vivo mice studies by establishing xenografts using the A549IL-6si/sc cell set. We next examined the mechanism by which IL-6 mediates cisplatin resistance by performing studies of qPCR, Western analyses, and applying inhibitors of intracellular signaling molecules. Finally, we independently developed the cisplatin resistant A549 (A549CisR) and H157(H157CisR) cell lines and investigated whether targeting IL-6 signaling using a neutralizing antibody of IL-6 could prime these cicplatin-resistant cells to increase the sensitivity to cisplatin. Results: The in vitro survival tests revealed that cisplatin was more cytotoxic to the IL-6 knocked down A549IL-6si and H157IL-6si cells than sc control cells. In in vivo mice studies, we consistently observed more effective tumor regression in A549IL-6si cells-derived xenografts than sc cells-derived tumors (control) after cisplatin treatments. In mechanistic studies, we found that expressions of the anti-apoptotic proteins (Bcl-2 and Mcl-1) and the molecules associated with DNA repair (ATM, CHK1, TP73, p53, and ERCC1) were significantly increased upon cisplatin treatment in A549sc and H157sc cells, but not in IL-6si cells of A549 and H157. The molecular inhibitor studies further revealed that the activation of signaling pathways, such as Stat3, Akt, MAPK, and Erk, was responsible for the up-regulation of these molecules. Further, when we treated cisplatin resistant-A549 and H157 cell lines (A549CisR and H157CisR) with a neutralizing antibody of IL-6, we observed increased cell cytotoxicity. Conclusions and Impact: Our data support that the IL-6 signaling may be critical in conferring NSCLC cell resistance to cisplatin. In addition, we demonstrated that targeting IL-6 signaling could overcome the established acquired cisplatin resistance. Our observation supports a possible strategy to overcome cisplatin resistance through targeting IL-6 signaling or its downstream molecule(s) in treating NSCLC. Citation Format: Shan-zhou Duan, Ying Tsai, Peter Keng, Yongbing Chen, Soo Ok Lee, Yuhchyau Chen. IL-6 signaling modulates cisplatin resistance in non-small cell lung cancer via up-regulations of anti-apoptotic and DNA repair associated molecules. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 740. doi:10.1158/1538-7445.AM2015-740

Resistance To Fas-Mediated Apoptosis In Malignant Tumours Is Rescued By Kn-93 And Cisplatin Via Downregulation Of C-Flip Expression And Phosphorylation

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

Changes and Significance of Fas and Cflip in Apoptosis of Human Rhabdomyosarcoma Cells Induced by Combination of TRAIL and Cisplatin

P2-156: Effects of collagen IV on cisplatin-induced apoptosis of non-small cell lung cancer cells

BIM Induction of Apoptosis Triggered by EGFR-sensitive and Resistance Cell Lines of Non-Small-cell Lung Cancer

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

[Sensitivity of Two Cell Lines with Acquired Resistance to Gefitinib to Several Chemotherapeutic Drugs].

Cisplatin Augments FAS-mediated Apoptosis Through Lipid Rafts.

Critical role for c-FLIPL on Fas resistance in colon carcinoma cell line HT-29

3-MA Enhanced Chemosensitivity in Cisplatin Resistant Hypopharyngeal Squamous Carcinoma Cells via Inhibiting Beclin -1 Mediated Autophagy

C-Flip Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-induced Apoptosis by the Histone Deacetylase Inhibitor LBH589.

BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells

3′,4′,5′,5,7-Pentamethoxyflavone Sensitizes Cisplatin-Resistant A549 Cells to Cisplatin by Inhibition of Nrf2 Pathway

Knockdown of Focal Adhesion Kinase Reverses Colon Carcinoma Multicellular Resistance.

Analysis of Fas and Fas Ligand expression and function in lung cancer cell lines

The Cisplatin And Chal-24 Combination Synergistically Kills Cancer Cells Through Iap And C-Flip Degradation, Ripoptosome Formation And Autophagy-Mediated Apoptosis

Enhancement of the activities of c-Jun NH2 terminal kinase reverses drug resistance of ovarian cancer cells to cisplatin

Cell calcification reverses the chemoresistance of cancer cells via the conversion of glycolipid metabolism

The Identification of New c-FLIP Inhibitors for Restoring Apoptosis in TRAIL-Resistant Cancer Cells

Abstract 740: IL-6 Signaling Modulates Cisplatin Resistance in Non-Small Cell Lung Cancer Via Up-Regulations of Anti-Apoptotic and DNA Repair Associated Molecules